Phenobarbital

Generic Name: Phenobarbital

Brand Names: Donnatal, Luminal, Phenobarb, Phenohytro, Sezaby

Drug Type: Small Molecule

Chemical Formula: C_₁₂H_₁₂N_₂O_₃

CAS Number: 50-06-6

Unique Ingredient Identifier: YQE403BP4D

Background: A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.

Indication: For the treatment of all types of seizures except absence seizures.

Associated Conditions: Alcohol Withdrawal Syndrome, Anxiety, Febrile Convulsions, Hyperbilirubinemia, Insomnia, Menopausal Symptoms, Partial-Onset Seizures, Seizures, Generalized, Withdrawal Symptoms

Associated Therapies: Sedation

Clinical Trials

Efficacy of Intravenous Levetiracetam in Neonatal Seizures

Phase 1

Completed

Conditions: Neonatal Seizures

Interventions: Drug: Intravenous phenobarbital
Drug: Intravenous levetiracetam

First Posted Date: 2012-11-02

Last Posted Date: 2019-08-21

Lead Sponsor: Richard H. Haas

Target Recruit Count: 280

Registration Number: NCT01720667

Locations: 🇺🇸
University of California, San Diego Medical Center / Neonatal Intensive Care Unit (NICU), San Diego, California, United States

Evaluation Phenobarbital as Adjunctive Therapy in Participants With Partial Onset Seizures

Phase 3

Completed

Conditions: Epilepsy

Interventions: Drug: Placebo tablet
Drug: Phenobarbital

First Posted Date: 2011-01-27

Last Posted Date: 2017-11-14

Lead Sponsor: West-Ward Pharmaceutical

Target Recruit Count: 314

Registration Number: NCT01284556

Locations: 🇵🇷
Centro Neurodiagnostico, Rio Piedras, Puerto Rico
🇵🇷
Hospital Del Maestro, San Juan, Puerto Rico
🇺🇸
Bluegrass Epilepsy Research, Lexington, Kentucky, United States

and more 1 locations

Effect of CYP2C9/CYP2C19 Polymorphism on Pharmacokinetics of Phenobarbital in Korean Neonatal Seizure Patients.

Not Applicable

Completed

Conditions: Neonatal Seizure

First Posted Date: 2010-10-20

Last Posted Date: 2012-01-31

Lead Sponsor: Yonsei University

Target Recruit Count: 52

Registration Number: NCT01224457

Phenobarbital for Acute Alcohol Withdrawal

Not Applicable

Completed

Conditions: Alcohol Withdrawal

Interventions: Drug: placebo
Drug: 10 mg/kg IV phenobarbital in 100 ml saline

First Posted Date: 2010-08-19

Last Posted Date: 2012-03-09

Lead Sponsor: Jonathan Rosenson

Target Recruit Count: 102

Registration Number: NCT01184417

Locations: 🇺🇸
Alameda County Medical Center, Oakland, California, United States

Clonidine for Neonatal Abstinence Syndrome Study

Not Applicable

Terminated

Conditions: Neonatal Abstinence Syndrome

Interventions: Drug: Clonidine
Drug: Phenobarbital

First Posted Date: 2010-08-05

Last Posted Date: 2014-01-06

Lead Sponsor: Baystate Medical Center

Target Recruit Count: 68

Registration Number: NCT01175668

Locations: 🇺🇸
NICU @ Baystate Children's Hospital, Springfield, Massachusetts, United States

Prophylactic Phenobarbital After Neonatal Seizures

Phase 4

Terminated

Conditions: Neonatal Seizures

Interventions: Drug: placebo
Drug: phenobarbital

First Posted Date: 2010-03-18

Last Posted Date: 2016-02-03

Lead Sponsor: University of Rochester

Target Recruit Count: 13

Registration Number: NCT01089504

Locations: 🇺🇸
Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States
🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
Akron Children's Hospital, Akron, Ohio, United States

and more 15 locations

Study of Phenobarbital Inhibition of Catamenial Epilepsy

Not Applicable

Withdrawn

Conditions: Epilepsy

Interventions: Other: Placebo
Drug: Phenobarbital

First Posted Date: 2007-09-17

Last Posted Date: 2014-12-10

Lead Sponsor: University of Toledo Health Science Campus

Registration Number: NCT00530413

Locations: 🇺🇸
University of Toledo, Health Science Campus, Toledo, Ohio, United States

Prediction of Childhood Epilepsy Outcome in Bangladesh

Not Applicable

Completed

Conditions: Epilepsy

First Posted Date: 2006-09-28

Last Posted Date: 2006-12-25

Lead Sponsor: Institute of Child Health

Target Recruit Count: 92

Registration Number: NCT00381537

Locations: 🇬🇧
Institute of Child Health, London, United Kingdom
🇧🇩
Children's Hospital Dhaka (Shishu) Bangladesh., Sher-e-Bangla Nagar, Dhaka 1207, Bangladesh

Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma

Phase 1

Completed

Conditions: Drug/Agent Toxicity by Tissue/Organ
Lymphoma
Neutropenia
Small Intestine Cancer
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: cyclosporine
Drug: irinotecan hydrochloride
Drug: phenobarbital

First Posted Date: 2004-03-26

Last Posted Date: 2013-02-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 3

Registration Number: NCT00002759

Locations: 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States

Antenatal Phenobarbital to Prevent Neonatal Intracranial Hemorrhage

Phase 3

Completed

Conditions: Infant, Newborn
Infant, Low Birth Weight
Intracranial Hemorrhages
Infant, Small for Gestational Age
Infant, Premature

Interventions: Drug: Phenobarbital
Drug: Saline

First Posted Date: 2001-02-05

Last Posted Date: 2019-03-22

Lead Sponsor: NICHD Neonatal Research Network

Target Recruit Count: 610

Registration Number: NCT00009620

Locations: 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸
George Washington University, Washington, District of Columbia, United States
🇺🇸
University of New Mexico, Albuquerque, New Mexico, United States

and more 8 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy